BIOCON | NEULAND LABS | BIOCON / NEULAND LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.4 | 69.4 | 49.5% | View Chart |
P/BV | x | 4.4 | 2.5 | 175.9% | View Chart |
Dividend Yield | % | 0.2 | 0.1 | 154.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
NEULAND LABS Mar-20 |
BIOCON / NEULAND LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 754 | 93.9% | |
Low | Rs | 554 | 247 | 223.9% | |
Sales per share (Unadj.) | Rs | 91.9 | 594.5 | 15.5% | |
Earnings per share (Unadj.) | Rs | 16.7 | 12.6 | 132.3% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 37.0 | 65.3% | |
Dividends per share (Unadj.) | Rs | 1.00 | 2.00 | 50.0% | |
Dividend yield (eoy) | % | 0.2 | 0.4 | 39.7% | |
Book value per share (Unadj.) | Rs | 101.6 | 553.4 | 18.4% | |
Shares outstanding (eoy) | m | 600.00 | 12.83 | 4,676.5% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 0.8 | 815.0% | |
Avg P/E ratio | x | 37.7 | 39.6 | 95.3% | |
P/CF ratio (eoy) | x | 26.1 | 13.5 | 192.9% | |
Price / Book Value ratio | x | 6.2 | 0.9 | 686.0% | |
Dividend payout | % | 6.0 | 15.8 | 37.8% | |
Avg Mkt Cap | Rs m | 378,330 | 6,421 | 5,892.3% | |
No. of employees | `000 | 6.1 | 1.3 | 478.2% | |
Total wages/salary | Rs m | 11,653 | 1,236 | 943.1% | |
Avg. sales/employee | Rs Th | 8,994.3 | 5,949.4 | 151.2% | |
Avg. wages/employee | Rs Th | 1,900.7 | 963.8 | 197.2% | |
Avg. net profit/employee | Rs Th | 1,635.3 | 126.4 | 1,293.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 7,627 | 723.0% | |
Other income | Rs m | 1,444 | 39 | 3,716.9% | |
Total revenues | Rs m | 56,588 | 7,666 | 738.2% | |
Gross profit | Rs m | 15,883 | 1,019 | 1,558.9% | |
Depreciation | Rs m | 4,478 | 313 | 1,431.6% | |
Interest | Rs m | 709 | 216 | 328.7% | |
Profit before tax | Rs m | 12,140 | 529 | 2,294.0% | |
Minority Interest | Rs m | 9 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,123 | 367 | 578.3% | |
Profit after tax | Rs m | 10,026 | 162 | 6,185.8% | |
Gross profit margin | % | 28.8 | 13.4 | 215.6% | |
Effective tax rate | % | 17.5 | 69.4 | 25.2% | |
Net profit margin | % | 18.2 | 2.1 | 855.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 5,152 | 936.1% | |
Current liabilities | Rs m | 30,376 | 3,576 | 849.4% | |
Net working cap to sales | % | 32.4 | 20.7 | 156.7% | |
Current ratio | x | 1.6 | 1.4 | 110.2% | |
Inventory Days | Days | 68 | 105 | 65.0% | |
Debtors Days | Days | 86 | 91 | 94.1% | |
Net fixed assets | Rs m | 64,130 | 3,969 | 1,616.0% | |
Share capital | Rs m | 3,000 | 129 | 2,325.6% | |
"Free" reserves | Rs m | 57,980 | 6,971 | 831.8% | |
Net worth | Rs m | 60,980 | 7,100 | 858.9% | |
Long term debt | Rs m | 15,766 | 774 | 2,037.7% | |
Total assets | Rs m | 121,924 | 12,310 | 990.5% | |
Interest coverage | x | 18.1 | 3.5 | 524.8% | |
Debt to equity ratio | x | 0.3 | 0.1 | 237.2% | |
Sales to assets ratio | x | 0.5 | 0.6 | 73.0% | |
Return on assets | % | 8.8 | 3.1 | 286.9% | |
Return on equity | % | 16.4 | 2.3 | 720.2% | |
Return on capital | % | 16.8 | 9.5 | 177.1% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 5,187 | 299.0% | |
Fx outflow | Rs m | 10,399 | 1,593 | 652.9% | |
Net fx | Rs m | 5,107 | 3,594 | 142.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 573 | 2,013.6% | |
From Investments | Rs m | -7,138 | -487 | 1,466.3% | |
From Financial Activity | Rs m | -2,417 | -55 | 4,410.6% | |
Net Cashflow | Rs m | 2,103 | 33 | 6,450.9% |
Indian Promoters | % | 40.4 | 36.3 | 111.4% | |
Foreign collaborators | % | 20.6 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.4 | 63.7 | 13.2% | |
FIIs | % | 10.7 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 63.7 | 31.2% | |
Shareholders | 109,995 | 12,705 | 865.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: J.B.CHEMICALS SUVEN LIFE SCIENCES CIPLA CADILA HEALTHCARE VENUS REMEDIES
Compare BIOCON With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
After opening the day on a strong note, Indian share markets witnessed a sharp sell-off during closing hours today and ended lower.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More